202 related articles for article (PubMed ID: 30496465)
1. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
Srivastava S; Deshpande D; Magombedze G; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
[TBL] [Abstract][Full Text] [Related]
2. Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
Srivastava S; Deshpande D; Magombedze G; van Zyl J; Cirrincione K; Martin K; Bendet P; Berg A; Hanna D; Romero K; Hermann D; Gumbo T
J Antimicrob Chemother; 2020 Feb; 75(2):392-399. PubMed ID: 31713607
[TBL] [Abstract][Full Text] [Related]
3. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
7. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
8. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
Srivastava S; Pasipanodya JG; Ramachandran G; Deshpande D; Shuford S; Crosswell HE; Cirrincione KN; Sherman CM; Swaminathan S; Gumbo T
EBioMedicine; 2016 Apr; 6():126-138. PubMed ID: 27211555
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
10. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
[TBL] [Abstract][Full Text] [Related]
11. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
12. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating
Srivastava S; Cirrincione KN; Deshpande D; Gumbo T
Front Pharmacol; 2020; 11():616294. PubMed ID: 33542690
[No Abstract] [Full Text] [Related]
13. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
15. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
16. Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
Magombedze G; Pasipanodya JG; Srivastava S; Deshpande D; Visser ME; Chigutsa E; McIlleron H; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S349-S358. PubMed ID: 30496464
[TBL] [Abstract][Full Text] [Related]
17. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
[TBL] [Abstract][Full Text] [Related]
18. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
Andries K; Gevers T; Lounis N
Antimicrob Agents Chemother; 2010 Nov; 54(11):4540-4. PubMed ID: 20713662
[TBL] [Abstract][Full Text] [Related]
20. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]